Clinical Trials
19 trialsNCT03573700 2026-05-20
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 1/2 Active not recruiting
NCT01384513 2026-04-15
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Phase 2 Completed
NCT05537766 2026-03-10
ZUMA-25
Gilead Sciences
Phase 2 Terminated
NCT05714345 2026-03-02
EXPAND
Allogene Therapeutics
Phase 2 Terminated
NCT03263936 2025-10-16
Epigenetic Reprogramming in Relapse/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT05883449 2025-08-20
LuminICE-203
Affimed GmbH
Phase 2 Terminated
NCT02614066 2024-11-19
ZUMA-3
Gilead Sciences
Phase 1/2 Completed
NCT03056339 2024-03-25
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03624036 2023-11-18
ZUMA-8
Gilead Sciences
Phase 1 Terminated
NCT03215810 2023-07-24
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT04030195 2023-01-31
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
Precision BioSciences, Inc.
Phase 1/2 Completed
NCT03168438 2022-01-11
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
GlaxoSmithKline
Phase 1 Terminated
NCT02761915 2021-08-17
A Phase I Trial of Anti-GD2 T-cells (1RG-CART)
Cancer Research UK
Phase 1 Completed
NCT01861002 2021-06-09
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT01289457 2020-02-24
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01499147 2018-11-08
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
University of Illinois at Chicago
Phase NA Completed
NCT01173679 2017-04-14
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL
Massachusetts General Hospital
Phase 2 Terminated
NCT00683046 2016-11-22
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
University of Chicago
Phase 2 Completed
NCT00615589 2016-04-04
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
University of Michigan Rogel Cancer Center
Phase 2 Terminated